Examkin

Soru

Zorluk: ZorEnd-of-Life and Palliative Care

A 65-year-old man with metastatic prostate cancer presents to the palliative care clinic with severe, constant lower back and pelvic pain. He is currently opioid-naive, and his pain is poorly controlled despite maximum scheduled doses of nonsteroidal anti-inflammatory drugs (NSAIDs). An evaluation confirms the pain is primarily nociceptive secondary to osseous metastases. The physician decides to initiate strong opioid therapy.

Arrange the following steps in the most appropriate chronological sequence for safely establishing and optimizing a long-term opioid regimen for this opioid-naive patient, from initial prescribing to long-term maintenance.

  1. 1Initiate an immediate-release opioid to safely titrate analgesia and concurrently start a prophylactic bowel regimen.
  2. 2Calculate the total daily dose of the immediate-release opioid consumed over a 24- to 48-hour period of stable pain control.
  3. 3Convert the calculated total daily opioid requirement into a scheduled, extended-release opioid formulation.
  4. 4Calculate and prescribe an as-needed, immediate-release opioid for breakthrough pain based on the new extended-release dose.
  5. 5Monitor during maintenance therapy for signs of opioid-induced neurotoxicity requiring potential opioid rotation.

Cevap

The correct sequence begins with initiating an immediate-release opioid alongside a bowel regimen, followed by calculating the total daily requirement once stable. This requirement is then converted to an extended-release formulation, supplemented with a proportionally calculated breakthrough dose, and finally, followed by long-term monitoring for toxicity.
The established standard of care for initiating strong opioids in opioid-naive patients involves safely titrating with short-acting medications, establishing a reliable 24-hour requirement, converting to a long-acting maintenance dose, adding an appropriate breakthrough pain regimen, and continually monitoring for long-term toxicity.

Adım Adım Çözüm

1
Select the initial prescribing step for an opioid-naive patient.
Initiate an immediate-release opioid to safely titrate analgesia and concurrently start a prophylactic bowel regimen.
Starting with extended-release opioids in naive patients risks fatal respiratory depression. Immediate-release formulations allow safe titration. Constipation prophylaxis is mandatory from day one.
2
Determine the necessary calculation after achieving initial pain control.
Calculate the total daily dose of the immediate-release opioid consumed over a 24- to 48-hour period of stable pain control.
To transition to long-acting therapy, the physician must first establish the patient's actual 24-hour baseline requirement based on their as-needed usage.
3
Select the step for establishing long-term baseline analgesia.
Convert the calculated total daily opioid requirement into a scheduled, extended-release opioid formulation.
Consolidating the daily requirement into an extended-release medication provides consistent round-the-clock pain relief and prevents the patient from having to wake up frequently to take medication.
4
Identify the step to manage incidental or flare-up pain on a maintenance regimen.
Calculate and prescribe an as-needed, immediate-release opioid for breakthrough pain based on the new extended-release dose.
Breakthrough pain is common despite adequate baseline analgesia. A rescue dose is standardly calculated at 10% to 20% of the total daily extended-release dose.
5
Select the long-term maintenance step.
Monitor during maintenance therapy for signs of opioid-induced neurotoxicity requiring potential opioid rotation.
Over time, high doses or declining renal function can cause toxic metabolite accumulation (e.g., from morphine), leading to neurotoxicity that requires rotating to a different opioid.

Anahtar Kavram

The safe initiation of strong opioids in naive patients requires starting with short-acting agents to determine the true daily requirement, followed by conversion to long-acting agents with a calculated supplemental breakthrough dose.
Tahmini Süre:1m 30s
Bu soruyu puanla

Konular

End-of-Life and Palliative Care

Bu konudan daha fazla soru